ES2150443T3 - Derivados de benzodiazepina y conjugados proteicos y polipeptidicos de los indicados derivados. - Google Patents

Derivados de benzodiazepina y conjugados proteicos y polipeptidicos de los indicados derivados.

Info

Publication number
ES2150443T3
ES2150443T3 ES93908664T ES93908664T ES2150443T3 ES 2150443 T3 ES2150443 T3 ES 2150443T3 ES 93908664 T ES93908664 T ES 93908664T ES 93908664 T ES93908664 T ES 93908664T ES 2150443 T3 ES2150443 T3 ES 2150443T3
Authority
ES
Spain
Prior art keywords
derivatives
polipeptidic
benzodiazepina
conjugates
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93908664T
Other languages
English (en)
Inventor
Kenneth Francis Buechler
Joseph Barry Noar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alere San Diego Inc
Original Assignee
Biosite Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosite Diagnostics Inc filed Critical Biosite Diagnostics Inc
Application granted granted Critical
Publication of ES2150443T3 publication Critical patent/ES2150443T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE DIRIGE A NUEVOS DERIVADOS DE BENZODIAZEPINA QUE SON SINTETIZADOS PARA LA UNION COVALENTE A ANTIGENOS (PROTEINAS O POLIPEPTIDOS) PARA LA PREPARACION DE ANTICUERPOS O RECEPTORES PARA METABOLITOS DE BENZODIAZEPINA. LOS NUEVOS ANTIGENOS RESULTANTES PUEDEN SER USADOS PARA LA PRODUCCION DE ANTICUERPOS O RECEPTORES USANDO METODOS NORMALIZADOS. UNA VEZ GENERADOS, LOS ANTICUERPOS O RECEPTORES Y LOS NUEVOS DERIVADOS QUE ESTAN COVALENTEMENTE UNIDOS A PROTEINAS, POLIPEPTIDOS O ETIQUETAS PUEDEN SER USADOS EN LOS PROCESOS DE INMUNOENSAYO.
ES93908664T 1992-04-06 1993-03-31 Derivados de benzodiazepina y conjugados proteicos y polipeptidicos de los indicados derivados. Expired - Lifetime ES2150443T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/864,093 US5302715A (en) 1992-04-06 1992-04-06 Benzodiazepine derivatives

Publications (1)

Publication Number Publication Date
ES2150443T3 true ES2150443T3 (es) 2000-12-01

Family

ID=25342514

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93908664T Expired - Lifetime ES2150443T3 (es) 1992-04-06 1993-03-31 Derivados de benzodiazepina y conjugados proteicos y polipeptidicos de los indicados derivados.

Country Status (9)

Country Link
US (1) US5302715A (es)
EP (1) EP0635016B1 (es)
JP (1) JPH07505632A (es)
AT (1) ATE193534T1 (es)
AU (1) AU3940593A (es)
CA (1) CA2132341A1 (es)
DE (1) DE69328779D1 (es)
ES (1) ES2150443T3 (es)
WO (1) WO1993020067A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037455A (en) * 1992-11-09 2000-03-14 Biosite Diagnostics Incorporated Propoxyphene derivatives and protein and polypeptide propoxyphene derivative conjugates and labels
DE19503320A1 (de) * 1995-02-02 1996-08-08 Boehringer Mannheim Gmbh Neue Benzodiazepinkonjugate
US5773003A (en) * 1995-03-31 1998-06-30 Immulogic, Inc. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
ES2210356T3 (es) * 1995-03-31 2004-07-01 Xenova Research Limited Conjugados de haptano-transportador para empleo en terapia contra el uso de drogas.
US5710256A (en) * 1995-04-03 1998-01-20 Biosite Diagnostics Incorporated Methadone derivatives and protein and polypeptide methadone derivative conjugates and labels
US6803040B1 (en) * 1995-08-22 2004-10-12 Biosite, Inc. Derivatives of tricyclic antidepressants and protein and polypeptide tricyclic antidepressant derivative conjugates and labels
US5706829A (en) * 1996-06-06 1998-01-13 Creighton University Method for treating neurocardiogenic syncope
US7202092B2 (en) * 2001-07-13 2007-04-10 Roche Diagnostics Operations, Inc. Indinavir derivatives useful in immunoassay
US7157561B2 (en) * 2001-07-13 2007-01-02 Roche Diagnostics Operations, Inc. Methods of inhibiting transmission of a costimulatory signal of lymphocytes
EP3160969B1 (en) 2014-06-26 2023-09-13 The Johns Hopkins University Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system
CN105601576A (zh) * 2016-03-18 2016-05-25 山东新华制药股份有限公司 氯甲西泮的晶型及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH538492A (de) * 1970-10-07 1973-06-30 Hoffmann La Roche Verfahren zur Herstellung von Benzodiazepin-Derivaten
US4046636A (en) * 1974-06-20 1977-09-06 Syva Company Diazepam enzyme conjugates
ATE154135T1 (de) * 1989-03-10 1997-06-15 Hoffmann La Roche Reagenzien zum nachweis von drogen

Also Published As

Publication number Publication date
AU3940593A (en) 1993-11-08
CA2132341A1 (en) 1993-10-14
JPH07505632A (ja) 1995-06-22
EP0635016A1 (en) 1995-01-25
WO1993020067A1 (en) 1993-10-14
US5302715A (en) 1994-04-12
DE69328779D1 (de) 2000-07-06
EP0635016A4 (en) 1995-03-29
EP0635016B1 (en) 2000-05-31
ATE193534T1 (de) 2000-06-15

Similar Documents

Publication Publication Date Title
EP0635019A4 (es)
ES2110230T3 (es) Ensayo de rapamicina.
DK53687D0 (da) Peptid_fra htlv-iii-viruskappeprotein
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
AU1130392A (en) Synthetic htlv-iii peptides, compositions and uses thereof
EP0638067A4 (en) NEW PROPOXYPHENE DERIVATIVES AND THEIR PROTEIN AND POLYPEPTIDE LABELS AND CONJUGATES.
DE3574184D1 (en) Support material for the use in immunoassays
ES2150443T3 (es) Derivados de benzodiazepina y conjugados proteicos y polipeptidicos de los indicados derivados.
ES2090052T3 (es) Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y uso.
ES2088011T3 (es) Antagonistas de aminoacidos excitadores.
GR900100372A (el) Προιον ζευξεως πολυπεπτιδιου-αντισωματος για την παρεμποδιση τησπροσφυσεως κυτταρων.
DE69611037T2 (de) Methadonderivate und protein- und polypeptid-methadonkonjugate und markierte verbindungen
ATE196767T1 (de) Neue cocain-derivate und protein- und polypeptid- cocain-derivate, konjugate und markierte verbindungen
BR9105983A (pt) Anticorpos monoclonais que diferenciam entre proteinas de sequencias nativa e modificada
RU95104325A (ru) Коньюгаты антител с улучшенными свойствами
RU94026276A (ru) Рецепторы интерлейкина-12 и антител
EA199900934A1 (ru) Применение микрочастиц, содержащих адсорбированные на них белок и антитела, для получения фармацевтической композиции для интраназального введения
KR860008779A (ko) 항체 형성 화합물의 제조방법

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 635016

Country of ref document: ES